Faron Pharmaceuticals Oy · LSE:FARN
Faron Pharmaceuticals Oy — ESMO Congress 2025
9 slides from Faron Pharmaceuticals Oy's conference presentation, Oct 19, 2025
Slide 1: Macrophage reprogrammer Bexmarilimab Plus Azacitidine in Myelodysplastic Syndrome
Macrophage reprogrammer Bexmarilimab Plus Azacitidine in Myelodysplastic Syndrome: PK/PD and biomarker results from the Phase 1/2 BEXMAB Study Presenter: Mika Kontro, MD, PhD Amer M. Zeidan, Anthony S. Stein, Jesper Mickos, Brian J. Ball, Mikko Myllymäki, Johanna Rimpiläinen, Marja Pyörälä, Timo Sii
Slide 2: Declaration of Interests
DECLARATION OF INTERESTS Consulting Fees: Astellas Pharma AbbVie Jazz Pharmaceuticals Faron Pharmaceuticals Servier Ferring Ventures Scientific Advisory Board Membership: Proteina Faron Pharmaceuticals Mika Kontro, MD, PhD Content of this presentation is copyright and responsibility of the author. P
Slide 3: Clever-1 – a novel macrophage immune checkpoint
Clever-1 – a novel macrophage immune checkpoint Inhibition of Clever-1 with bexmarilimab converts anti-tumorigenic macrophages to pro-inflammatory and activates T cell response. 1,2 BEXMAB PhI/II study In MDS, bexmarilimab targets also blast cell energy production.3,4 Escalation (Phase I) Azacitidin
Slide 4: Bexmarilimab plus azacitidine is well tolerated in HR MDS
Bexmarilimab plus azacitidine is well tolerated in HR MDS Treatment-naïve r/r MDS Total (n=53), MDS (n=21) (n=32) Most common TEAEs Gr 1-2 ≥ Gr 3 n (%) Age, median (range) 72 (53-81) 74 (52-87) ECOG PS, n (%) Constipation 19 (35.8) 19 (35.8) 0 0 4 (19) 9 (28.1) Neutrophil count 19 (35.8) 1 (1.9) 18
Slide 5: Efficacy in HR treatment-naïve (TN) and r/r HR-MDS
Efficacy in HR treatment-naïve (TN) and r/r HR-MDS Treatment-naïve HR MDS Treatment-naïve (TN) r/r HR-MDS 4 5 10 15 5 12 3 4 18 15 12 17 10 3 13 1 1 13 5 3 Pre-treatment n, (%) 0 BM blast % HR-MDS (n=20) (n=32) CR 9 (45) 2 (6.3) Best % change in BM blasts -25 mCR 5 (25) 13 (40.6) 1 mg/kg 3 mg/kg PR
Slide 6: Pharmacokinetics and target engagement
Pharmacokinetics and target engagement TN HR MDS - C1D28 BM r/r MDS – C1D28 BM Bexmarilimab serum concentration (µg/mL) Cycle 1 0 0 100.00 6 mg/kg Percentage change from baseline Percentage change from baseline 3 mg/kg 1 mg/kg -20 -20 10.00 -40 -40 1.00 -60 -60 0.10 -80 -80 0.01 -100 -100 05 24 48 7
Slide 7: Deeper bone marrow target engagement in responding patients
Deeper bone marrow target engagement in responding patients, especially in patients with less than 5% blasts Significantly better BM target engagement Significantly better BM target engagement in responding patients (p=0.0006) in responding patients with less than 5% baseline blast count -20 0 Perce
Slide 8: Summary
Summary Bexmarilimab plus azacitidine shows promising efficacy in HR MDS Safety Efficacy Biomarkers • Safety profile manageable • 45% CR rate and 85% • Higher BM target and consistent with ORR rate in treatment- engagement in azaciditine alone in HR naïve HR-MDS (IWG responding patients MDS 2006) •
Slide 9: Acknowledgements
Trial participants, and their families for their participation. Helsinki University Hospital, FI Tampere University Hospital, FI MD Anderson Cancer Center, US Christie NHS Foundation Trust, UK Preclinical work Mikko Myllymäki Johanna Rimpiläinen Naval Daver Emma Searle Sirpa Jalkanen Nicole Koskinen